MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
3.310
-0.300
-8.31%
After Hours: 3.340 +0.03 +0.91% 17:42 05/15 EDT
OPEN
3.500
PREV CLOSE
3.610
HIGH
3.580
LOW
3.305
VOLUME
3.19M
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.240
MARKET CAP
539.71M
P/E (TTM)
-1.6898
1D
5D
1M
3M
1Y
5Y
1D
Morgan Stanley Remains a Buy on Cabaletta Bio (CABA)
TipRanks · 16h ago
Cabaletta Bio Price Target Raised to $4.00/Share From $2.00 by Wells Fargo
Dow Jones · 16h ago
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Dow Jones · 16h ago
Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4
Benzinga · 16h ago
Wells Fargo Gives a Hold Rating to Cabaletta Bio (CABA)
TipRanks · 18h ago
Cabaletta Bio (CABA) Receives a Buy from Guggenheim
TipRanks · 18h ago
CABALETTA BIO, INC. <CABA.O>: WELLS FARGO RAISES TARGET PRICE TO $4 FROM $2
Reuters · 19h ago
Douglas Tsao Reiterates Buy on Cabaletta Bio, Maintains $16 Price Target on Rese-cel’s Emerging Commercial Profile and Conditioning-Free Edge
TipRanks · 19h ago
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.